Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, 230032, China.
Institute for Liver Diseases of Anhui Medical University, Hefei, 230032, China.
Acta Pharmacol Sin. 2021 Oct;42(10):1676-1689. doi: 10.1038/s41401-020-00575-3. Epub 2021 Jan 29.
Zinc finger E-box-binding homeobox 1 (ZEB1), a functional protein of zinc finger family, was aberrant expressed in many kinds of liver disease including hepatic fibrosis and Hepatitis C virus. Bioinformatics results showed that ZEB1 was abnormally expressed in HCC tissues. However, to date, the potential regulatory role and molecular mechanisms of ZEB1 are still unclear in the occurrence and development of HCC. This study demonstrated that the expression level of ZEB1 was significantly elevated both in liver tissues of HCC patients and cell lines (HepG2 and SMMC-7721 cells). Moreover, ZEB1 could promote the proliferation, migration, and invasion of HCC cells. On the downstream regulation mechanism, ZEB1 could activate the Wnt/β-catenin signaling pathway by upregulating the protein expression levels of β-catenin, c-Myc, and cyclin D1. Novel studies showed that miR-708 particularly targeted ZEB1 3'-UTR regions and inhibited the HCC cell proliferation, migration, and invasion. Furthermore, results of nude mice experiments of HCC model indicated that miR-708 could inhibit tumor growth and xenograft metastasis model was established to validate that miR-708 could inhibit HCC cell metastasis through tail-vein injection in vivo. Together, the study suggested that ZEB1 modulated by miR-708 might be a potential therapeutic target for HCC therapy.
锌指 E 盒结合同源盒 1(ZEB1)是锌指家族的一种功能蛋白,在包括肝纤维化和丙型肝炎病毒在内的多种肝病中异常表达。生物信息学结果表明,ZEB1 在 HCC 组织中异常表达。然而,迄今为止,ZEB1 在 HCC 发生和发展中的潜在调节作用和分子机制仍不清楚。本研究表明,ZEB1 在 HCC 患者和细胞系(HepG2 和 SMMC-7721 细胞)的肝组织中表达水平显著升高。此外,ZEB1 可以促进 HCC 细胞的增殖、迁移和侵袭。在下游调控机制方面,ZEB1 可以通过上调β-catenin、c-Myc 和 cyclin D1 的蛋白表达水平来激活 Wnt/β-catenin 信号通路。新的研究表明,miR-708 特别靶向 ZEB1 的 3'-UTR 区域,并抑制 HCC 细胞的增殖、迁移和侵袭。此外,HCC 模型裸鼠实验结果表明,miR-708 可抑制肿瘤生长,并通过尾静脉注射建立 HCC 细胞转移的异种移植转移模型,验证了 miR-708 可通过体内尾静脉注射抑制 HCC 细胞转移。总之,该研究表明,miR-708 调节的 ZEB1 可能是 HCC 治疗的潜在治疗靶点。